Search PubMed⌕ Search

Biomedical subjects

M Samama

Publications and source records attributed to M Samama.

At least 361 records · Page 20Linked to original sources
PubMedDate not supplied

[Sclerotherapy of varices and protein C deficiency].

The appearance of relapsing venous thrombosis after sclerosis of varices in a woman aged 30 led us to discover a quantitative protein C deficiency, found in her father and 4 of her brothers and sisters. The transmission mode is autosomal and dominant. Within this family, 6 subjects are affected, 4 showing symptoms, clearly showing the heterogeneity of the clinical manifestation of the deficiency. Dealing with the special problem of pregnancy in women with the biological disorder, one ought to consider the literature on the subject, showing the large occurrence of ante- and post-natal accidents. The treatments of thromboembolic complications is based on the use of heparin administered appropriately through antivitamins K for a period which is till to be defined. In asymptomatic subjects, a preventive anticoagulant treatment is recommended in all circumstances likely to encourage the relapse of thrombosis.

Adult↗
PubMedDate not supplied

[Prevention of postoperative thrombo-embolic accidents following thoracic surgery by low-dose calcium heparinate: a comparative study (author's transl)].

A comparative clinical trial was undertaken in 2420 patients undergoing thoracic surgery during a 4-year period (1973-1977); 40% of the patients had bronchial cancer. Random allocation was not considered as being possible by the surgeons and was replaced by allocation according to the time of operation. There were three protocol groups: Protocol A: First morning operations (1007 patients): subcutaneous calcium heparin, 5000 units (Ul) 2 hours and 30 minutes before surgery then every 12 hours for 15 days. Protocol B: Second morning operations (932 patients): same dose and duration of treatment; the first injection took place 24 to 72 hours after the surgical procedure. The doses were increased from the fourth day after surgery in order to obtain a moderately prolonged partial thromboplastin time (difference patient-control: 7 to 14 seconds). Protocol 0: 481 patients received no anticoagulant treatment because of a contraindication or minor surgical procedure. Preliminary results showed and increase of per-operative bleeding (p less than 0.01) in treated patients; this was very well accepted by the surgeons. Among the heparin-treated patients, 11 pulmonary emboli out of 13 were observed in patients with bronchial cancer. Of these 13, 10 were fatal with 9 being verified at autopsy. The pulmonary emboli episodes occurred significantly earlier in protocol B than in protocol A. Fatal pulmonary embolism in patients with bronchial cancer was significantly more frequent in protocol B (7 cases) than in protocol A (1 case); P less than 0.01. These results have shown a low frequency of fatal pulmonary emboli in patients without bronchial cancer receiving twice-daily subcutaneous injections of heparin (2 of 1102 operated subjects). The rate was higher in patients with bronchial cancer and this results supports a recommended thrice-daily dose in such patients. In addition, the pre-operative administration of heparin is useful in preventing early post-operative pulmonary embolism.

Adult↗
PubMedDate not supplied

[Effect of flurbiprofen on platelet functions. Study of its interference with the synthesis of platelet thromboxane and production of prostacyclin by the rabbit aorta].

The effect of flurbiprofen has been studied on the platelet aggregation of a human platelet rich plasma in the presence of 3 different inducers: ADP, collagen and arachidonic acid. Flurbiprofen is a potent inhibitor of platelet aggregation as compared to aspirin (160 to 2200 more potent). This inhibition was also found using isolated platelets stimulated by arachidonic acid where the suppression of the thromboxane synthesis was accompanied by the inhibition of 14C-serotonin release as well as of aggregation. The administration of flurbiprofen to rabbits, 1 and 3 mg/kg during 3 days was followed by an inhibition of the collagen-induced platelet reactivity. The aortic prostacyclin synthesis as studied by its biological activity was also inhibited at 3 mg/kg (p less than 0,01) but less significantly at 1 mg/kg. The more potent action of flurbiprofen compared to that of aspirin as well as its rapid reversibility would allow the use of this drug for the inhibition of some of the platelet functions.

Adenosine Diphosphate↗